New Therapeutic Options in the Prevention and Management of Migraines: How Emerging CGRP Therapies Could Change the Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2019 to January 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Alder BioPharmaceuticals and Teva Pharmaceuticals

Description:
According to the World Health Organization (WHO), Migraine is ranked in the top fifteen most disabling medical conditions. It is a major neurological disease and affects more than 36 million people in the United States. It is believed that a substantial number of people with the condition remain undiagnosed, which stresses the importance of proper screening and diagnostic tools and strategies. Patients with frequent migraines and/or who experience functional disability need preventative migraine treatment. The fact that diagnosis is based entirely on clinical history poses a challenge for healthcare professionals, as migraine is only 1 of approximately 300 headache disorders. A new class of therapy is emerging that has shown to offer vastly improved efficacy and safety over traditional treatment regimens. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are under clinical investigation and look to offer healthcare professionals a new and improved armamentarium in the treatment and prevention of migraines. CGRP monoclonal antibodies are specifically designed to bind to and inhibit the activity of CGRP that may prevent or significantly reduce the frequency of monthly migraine headache days in patients with episodic and chronic migraine and cluster headache. The role of CGRP in migraine has been verified by basic research and several therapies are currently undergoing late stage clinical trials.

Upon completion of this activity, participants will be able to:

  • Evaluate the potential challenges in reaching an accurate migraine diagnosis, and the impact of migraine on patient quality of life and societal costs

  • Analyze recent clinical trial information, including safety and efficacy data, on emerging CGRP monoclonal antibodies in the prevention and management of migraines

  • Explore the managed care considerations of emerging CGRP therapies by exploring where these potential agents may fit into current chronic migraine management paradigm

  • Compare and contrast emerging CGRP agents in development for the treatment of migraine

  • Recognize the impact migraine has on pharmacoeconomics and total cost of patient care

  • Examine a patient-centered approach to the care of patients with migraine in order to improve outcomes, patient education and satisfaction, and treatment adherence
     

Faculty: Andrew Charles, M.D.
Professor
Director, UCLA Goldberg Migraine Program
Mayer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at UCLA

Disclosure:

Dr. Charles serves on an advisory board for Alder, Biohaven, eNeura, and Eli Lilly. He serves as a consultant for Amgen. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Alder BioPharmaceuticals and Teva Pharmaceuticals.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue